Form 4: ADMA Director Alison Finger Boosts Stake with Equity Grants

ADMA Biologics Director Alison Finger received grants of 10,690 restricted stock units and 17,730 stock options, increasing her beneficial ownership.

Summary

• Alison Cecily Finger, a Director of ADMA Biologics, Inc. (ADMA), acquired 10,690 Restricted Stock Units (RSUs) and 17,730 stock options on February 9, 2026.
• The RSUs were granted at a price of $0 and will vest in two equal installments on the sixand 12-month anniversaries of the grant date, becoming fully vested on February 9, 2027, contingent on continued service.
• The stock options were granted at a price of $0, have an exercise price of $16.37, and will vest in twelve equal monthly installments, becoming fully vested on February 9, 2027, with an expiration date of February 9, 2036.
• Following these transactions, Ms. Finger beneficially owns 45,619 shares of common stock, which includes the newly granted 10,690 RSUs, 5,445 previously granted RSUs (vesting February 19, 2026), and 29,484 directly owned common shares.
• Additionally, she beneficially owns 17,730 derivative securities in the form of stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating a director's increased stake and alignment with the company's future performance through equity compensation, which is a standard practice.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with long-term shareholder value.
• An increase in a director's beneficial ownership, even through grants, can signal confidence in the company's future prospects.

Negatives

• The acquisition was through grants, not open market purchases, meaning no direct cash investment by the director at the time of grant.

Risks

• The vesting of both the restricted stock units and stock options is subject to the Reporting Person's continued service as of the applicable vesting dates.

Future Outlook

The grants of RSUs and stock options with future vesting dates indicate a continued commitment from the director to the company's long-term performance, as the full realization of value is contingent on continued service and potential stock price appreciation.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options, are a standard component of executive and director compensation packages in the biotechnology and pharmaceutical sectors. This practice aims to align the interests of company leadership with those of shareholders by tying a significant portion of their compensation to the company's stock performance and long-term success.

Comparison to Industry Standards

• StockSavvy.ai observes that equity compensation packages for directors in the biotechnology sector, such as those seen at companies like Regeneron Pharmaceuticals or Amgen, often include a mix of restricted stock units and stock options.
• The vesting schedules tied to continued service, as seen in this ADMA grant, are a common mechanism across the industry to ensure retention and long-term commitment from key personnel.
• The exercise price for options, when granted at market price on the grant date (or $0 for a grant), is typical for incentive-based compensation.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with the company's stock performance, potentially encouraging decisions that benefit long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Vesting of 5,445 RSUs on February 19, 2026.
• Vesting of the newly granted 10,690 RSUs in two equal installments on the sixand 12-month anniversaries of February 9, 2026.
• Vesting of the 17,730 stock options in twelve equal monthly installments, becoming fully vested on February 9, 2027.

Key Dates

Recommendation

This Form 4 details a routine equity grant to a director as part of their compensation, which is a neutral to slightly positive signal of alignment. It does not provide sufficient new information regarding the company's operational or financial performance to warrant a change in investment recommendation based solely on this filing. Investors should consider broader company fundamentals and market conditions.

Keywords

ADMA Biologics, ADMA, Form 4, Insider Transaction, Director, Restricted Stock Units, RSU, Stock Options, Equity Grant, Beneficial Ownership